MX2021005150A - Moleculas de anticuerpos anti tnfr2 antagonistas novedosas. - Google Patents
Moleculas de anticuerpos anti tnfr2 antagonistas novedosas.Info
- Publication number
- MX2021005150A MX2021005150A MX2021005150A MX2021005150A MX2021005150A MX 2021005150 A MX2021005150 A MX 2021005150A MX 2021005150 A MX2021005150 A MX 2021005150A MX 2021005150 A MX2021005150 A MX 2021005150A MX 2021005150 A MX2021005150 A MX 2021005150A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody molecules
- antagonistic anti
- tnfr2 antibody
- novel antagonistic
- tnfr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen moléculas de anticuerpos antagonistas novedosas que se fijan específicamente al TNFR2 en una célula objetivo y, por lo tanto, bloquean la fijación de TNFa a TNFR2 y que bloquean a la señalización de TNFR2, en donde las moléculas de anticuerpo también se fijan a receptores Fc a través de la región Fc.; también se describe el uso de tales moléculas de anticuerpos en el tratamiento de cáncer o infecciones causadas por patógenos intracelulares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18203993 | 2018-11-01 | ||
PCT/EP2019/080004 WO2020089474A1 (en) | 2018-11-01 | 2019-11-01 | Novel antagonistic anti tnfr2 antibody molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021005150A true MX2021005150A (es) | 2021-07-15 |
Family
ID=64109794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005150A MX2021005150A (es) | 2018-11-01 | 2019-11-01 | Moleculas de anticuerpos anti tnfr2 antagonistas novedosas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220073634A1 (es) |
EP (1) | EP3873936A1 (es) |
JP (1) | JP2022512905A (es) |
KR (1) | KR20210087029A (es) |
CN (1) | CN112955469A (es) |
AU (1) | AU2019372184A1 (es) |
BR (1) | BR112021007995A2 (es) |
CA (1) | CA3117864A1 (es) |
IL (1) | IL282715A (es) |
MX (1) | MX2021005150A (es) |
WO (1) | WO2020089474A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023529010A (ja) | 2020-06-12 | 2023-07-06 | ナンチン リーズ バイオラブス カンパニー,リミティド | Tnfr2に結合する抗体およびその用途 |
US20240109974A1 (en) * | 2021-01-29 | 2024-04-04 | Shandong Simcere Biopharmaceutical Co., Ltd. | Humanized antibody against tnfr2 and use thereof |
EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB-特异性抗体及其使用方法 |
CN1997667A (zh) * | 2004-05-10 | 2007-07-11 | 宏观基因有限公司 | 人源化FcγRⅡB特异性抗体及其使用方法 |
EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
WO2016156291A1 (en) * | 2015-03-31 | 2016-10-06 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a trimeric tnf family ligand |
WO2016187068A1 (en) * | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
US10988543B2 (en) * | 2015-11-11 | 2021-04-27 | Opi Vi—Ip Holdco Llc | Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor |
CN116715767A (zh) * | 2016-05-13 | 2023-09-08 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
ES2941972T3 (es) * | 2016-06-22 | 2023-05-29 | Univ Paris Val De Marne | Prevención o tratamiento de la recaída de neoplasias malignas hematológicas mediante un antagonista de TNFR2 |
-
2019
- 2019-11-01 KR KR1020217012926A patent/KR20210087029A/ko active Search and Examination
- 2019-11-01 BR BR112021007995-5A patent/BR112021007995A2/pt unknown
- 2019-11-01 AU AU2019372184A patent/AU2019372184A1/en active Pending
- 2019-11-01 EP EP19805901.6A patent/EP3873936A1/en active Pending
- 2019-11-01 JP JP2021523957A patent/JP2022512905A/ja active Pending
- 2019-11-01 CA CA3117864A patent/CA3117864A1/en active Pending
- 2019-11-01 CN CN201980071097.6A patent/CN112955469A/zh active Pending
- 2019-11-01 US US17/290,352 patent/US20220073634A1/en active Pending
- 2019-11-01 WO PCT/EP2019/080004 patent/WO2020089474A1/en unknown
- 2019-11-01 MX MX2021005150A patent/MX2021005150A/es unknown
-
2021
- 2021-04-27 IL IL282715A patent/IL282715A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021007995A2 (pt) | 2021-08-10 |
WO2020089474A8 (en) | 2021-06-24 |
KR20210087029A (ko) | 2021-07-09 |
CN112955469A (zh) | 2021-06-11 |
CA3117864A1 (en) | 2020-05-07 |
IL282715A (en) | 2021-06-30 |
JP2022512905A (ja) | 2022-02-07 |
EP3873936A1 (en) | 2021-09-08 |
AU2019372184A1 (en) | 2021-05-27 |
WO2020089474A1 (en) | 2020-05-07 |
US20220073634A1 (en) | 2022-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005150A (es) | Moleculas de anticuerpos anti tnfr2 antagonistas novedosas. | |
PH12017502129A1 (en) | Antibodies against ox40 and uses thereof | |
MX2021013586A (es) | Anticuerpo monoclonal anti-antigeno 4 asociado a linfocitos t citotoxicos (ctla4) o su fragmento de union a antigeno, una composicion farmaceutica y uso. | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
WO2019224716A3 (en) | Antibodies specific for gucy2c and uses thereof | |
PH12016500291A1 (en) | Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof | |
EA201890390A8 (ru) | БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3 | |
EA201591495A1 (ru) | Гуманизированные антитела против cd134 (ox40) и применения указанных антител | |
MX2021005151A (es) | Novedosas moleculas de anticuerpos anti-tnfr2 agonistas. | |
PH12020552229A1 (en) | Il-11ra antibodies | |
PH12015501656A1 (en) | Anti-il-33 antibodies and use thereof | |
MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
MX2019013753A (es) | Combinaciones de inmunoconjugados anti-folr1 y anticuerpo anti-pd-1. | |
EA202092302A1 (ru) | Антитела к trem-1 и их применения | |
EA201992145A1 (ru) | Анти-pd-l1-анти-tim-3 биспецифические антитела | |
PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
EA202090533A3 (ru) | Антитела к ox40 и их применение |